ETON vs. ESPR
ETON (Eton Pharmaceuticals Inc) and ESPR (Esperion Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — ETON in Drug Manufacturers - Specialty & Generic, ESPR in Biotechnology. Over the past 5 years, ETON returned 36.00%/yr vs -34.62%/yr for ESPR. At a 0.20 correlation, their price movements are largely independent.
Performance
ETON vs. ESPR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ETON achieves a 86.81% return, which is significantly higher than ESPR's -14.86% return.
ETON
- 1D
- -1.62%
- 1M
- 2.50%
- YTD
- 86.81%
- 6M
- 89.16%
- 1Y
- 117.71%
- 3Y*
- 102.22%
- 5Y*
- 36.00%
- 10Y*
- —
ESPR
- 1D
- 0.00%
- 1M
- 0.96%
- YTD
- -14.86%
- 6M
- -18.18%
- 1Y
- 162.50%
- 3Y*
- 35.36%
- 5Y*
- -34.62%
- 10Y*
- -14.95%
ETON vs. ESPR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
ETON Eton Pharmaceuticals Inc | 86.81% | 26.95% | 204.11% | 55.32% | -34.27% | -47.23% | 12.92% | 17.65% | -4.23% |
ESPR Esperion Therapeutics, Inc. | -14.86% | 68.18% | -26.42% | -52.01% | 24.60% | -80.77% | -56.40% | 29.63% | -8.49% |
Correlation
The correlation between ETON and ESPR is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Nov 13, 2018 | 0.20 |
Fundamentals
ETON:
$996.57M
ESPR:
$791.76M
ETON:
-$0.05
ESPR:
-$0.03
ETON:
10.20
ESPR:
1.75
ETON:
$86.93M
ESPR:
$418.24M
ETON:
$47.61M
ESPR:
$226.32M
ETON:
$5.70M
ESPR:
$77.18M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ETON vs. ESPR — Risk / Return Rank
ETON
ESPR
ETON vs. ESPR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Eton Pharmaceuticals Inc (ETON) and Esperion Therapeutics, Inc. (ESPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ETON | ESPR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.40 | ||
| Sortino ratioReturn per unit of downside risk | -0.02 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.36 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 3.27 | 3.07 | +0.20 |
| Martin ratioReturn relative to average drawdown | 6.73 | 7.68 | -0.95 |
Loading charts...
Drawdowns
ETON vs. ESPR - Drawdown Comparison
The maximum ETON drawdown since its inception was -79.94%, smaller than the maximum ESPR drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for ETON and ESPR.
Loading charts...
Drawdown Indicators
| ETON | ESPR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.94% | -99.37% | +19.43% |
Max Drawdown (1Y)Largest decline over 1 year | -36.17% | -53.19% | +17.02% |
Max Drawdown (3Y)Largest decline over 3 years | -45.65% | -80.94% | +35.29% |
Max Drawdown (5Y)Largest decline over 5 years | -70.42% | -97.16% | +26.74% |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.10% | — |
Current DrawdownCurrent decline from peak | -9.74% | -97.27% | +87.53% |
Average DrawdownAverage peak-to-trough decline | -37.58% | -69.99% | +32.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.56% | 21.30% | -3.74% |
Volatility
ETON vs. ESPR - Volatility Comparison
Eton Pharmaceuticals Inc (ETON) has a higher volatility of 17.63% compared to Esperion Therapeutics, Inc. (ESPR) at 1.06%. This indicates that ETON's price experiences larger fluctuations and is considered to be riskier than ESPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ETON | ESPR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.63% | 1.06% | +16.57% |
Volatility (6M)Calculated over the trailing 6-month period | 40.49% | 61.44% | -20.95% |
Volatility (1Y)Calculated over the trailing 1-year period | 54.85% | 92.66% | -37.81% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 63.41% | 91.79% | -28.38% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 63.87% | 84.61% | -20.74% |
Dividends
ETON vs. ESPR - Dividend Comparison
Neither ETON nor ESPR has paid dividends to shareholders.
Financials
ETON vs. ESPR - Financials Comparison
This section allows you to compare key financial metrics between Eton Pharmaceuticals Inc and Esperion Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ETON vs. ESPR - Profitability Comparison
ETON - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Eton Pharmaceuticals Inc reported a gross profit of 14.74M and revenue of 24.27M. Therefore, the gross margin over that period was 60.7%.
ESPR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 80.10M. Therefore, the gross margin over that period was 0.0%.
ETON - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Eton Pharmaceuticals Inc reported an operating income of 2.41M and revenue of 24.27M, resulting in an operating margin of 10.0%.
ESPR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported an operating income of -6.58M and revenue of 80.10M, resulting in an operating margin of -8.2%.
ETON - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Eton Pharmaceuticals Inc reported a net income of 1.55M and revenue of 24.27M, resulting in a net margin of 6.4%.
ESPR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a net income of -25.20M and revenue of 80.10M, resulting in a net margin of -31.5%.
Frequently Asked Questions
ETON and ESPR have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ETON has higher volatility (17.63%) compared to ESPR (1.06%). In terms of maximum drawdown, ETON dropped -79.94% vs ESPR's -99.37%.
ETON currently has the higher Sharpe Ratio (2.16 vs 1.76), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ETON and ESPR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer